Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2011

Open Access 01-12-2011 | Question and Answer

Q&A: Primary generalized glucocorticoid resistance

Author: George Chrousos

Published in: BMC Medicine | Issue 1/2011

Login to get access

Excerpt

PGGR means that all tissues in an organism have decreased sensitivity or "resistance" to the natural glucocorticoid, in us humans, cortisol. …
Appendix
Available only for authorised users
Metadata
Title
Q&A: Primary generalized glucocorticoid resistance
Author
George Chrousos
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2011
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-9-27

Other articles of this Issue 1/2011

BMC Medicine 1/2011 Go to the issue

Commentary

Acute kidney injury biomarkers: renal angina and the need for a renal troponin I

Review

The epidemic of sexually transmitted infections in China: implications for control and future perspectives

Commentary

Control of tuberculosis in large cities in developed countries: an organizational problem

Research article

Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials

Research article

A decision aid to rule out pneumonia and reduce unnecessary prescriptions of antibiotics in primary care patients with cough and fever

Research article

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models